Sarepta Therapeutics (SRPT) Tops Q2 EPS by $1.32

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $2.02, $1.32 better than the analyst estimate of $0.70. Revenue for the quarter came in at $611.09 million versus the consensus estimate of $532.86 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Full Circle Lithium closes $5.14M private placement